|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is the youngest case published to date of papillary craniopharyngioma with a confirmed BRAF V600E mutation.
|
30069716 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genetic analysis with whole-exome sequencing studies showed no differential mutations of CTNNB1 (β-catenin) and BRAF (V600E) between TC and NC subtypes, but there was a difference between adamantinomatous craniopharyngioma and papillary craniopharyngioma.
|
31200374 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genetic analysis with whole-exome sequencing studies showed no differential mutations of CTNNB1 (β-catenin) and BRAF (V600E) between TC and NC subtypes, but there was a difference between adamantinomatous craniopharyngioma and papillary craniopharyngioma.
|
31200374 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is the youngest case published to date of papillary craniopharyngioma with a confirmed BRAF V600E mutation.
|
30069716 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP.
|
29509940 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E and CTNNB1 in papCP and adaCP samples were sequenced by next-generation sequencing and the Sanger method, and mRNA expression levels of Axin2 and BMP4 were evaluated by RT-PCR.
|
30074466 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we first evaluated BRAF V600E and CTNNB1 mutations in four and 14 cases of pCP and aCP, respectively, using high-resolution melting analysis followed by Sanger sequencing.
|
28840946 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series.
|
30187175 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report.
|
29701552 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
OBJECTIVE Exome sequencing studies have recently demonstrated that papillary craniopharyngiomas (PCPs) and adamantinomatous craniopharyngiomas (ACPs) have distinct genetic origins, each primarily driven by mutually exclusive alterations: either BRAF ( V600E), observed in 95% of PCPs, or CTNNB1, observed in 75%-96% of ACPs.
|
28707994 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report.
|
29701552 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
OBJECTIVE Exome sequencing studies have recently demonstrated that papillary craniopharyngiomas (PCPs) and adamantinomatous craniopharyngiomas (ACPs) have distinct genetic origins, each primarily driven by mutually exclusive alterations: either BRAF ( V600E), observed in 95% of PCPs, or CTNNB1, observed in 75%-96% of ACPs.
|
28707994 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP.
|
29509940 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E and CTNNB1 in papCP and adaCP samples were sequenced by next-generation sequencing and the Sanger method, and mRNA expression levels of Axin2 and BMP4 were evaluated by RT-PCR.
|
30074466 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we first evaluated BRAF V600E and CTNNB1 mutations in four and 14 cases of pCP and aCP, respectively, using high-resolution melting analysis followed by Sanger sequencing.
|
28840946 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series.
|
30187175 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we reveal that papillary craniopharyngioma (PCP), a benign human pituitary tumour harbouring <i>BRAF p.V600E</i> also contains Sox2<sup>+</sup> cells with sustained proliferative capacity and disrupted pituitary differentiation.
|
28506993 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we reveal that papillary craniopharyngioma (PCP), a benign human pituitary tumour harbouring <i>BRAF p.V600E</i> also contains Sox2<sup>+</sup> cells with sustained proliferative capacity and disrupted pituitary differentiation.
|
28506993 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
|
26498373 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The authors have previously shown high mutation rates of BRAF V600E in papillary craniopharyngioma and of CTNNB1 in adamantinomatous craniopharyngioma.
|
27903124 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
|
26563980 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The authors have previously shown high mutation rates of BRAF V600E in papillary craniopharyngioma and of CTNNB1 in adamantinomatous craniopharyngioma.
|
27903124 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
|
26498373 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
|
26563980 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
|
25442675 |
2015 |